Loring Wolcott & Coolidge Fiduciary Advisors Llp Has Cut Its Intuit (INTU) Position; BioLine Rx Ltd (BLRX) Had 6 Analysts Last Week

February 23, 2018 - By Matt Maslow

Loring Wolcott & Coolidge Fiduciary Advisors Llp decreased Intuit (INTU) stake by 0.57% reported in 2017Q3 SEC filing. Loring Wolcott & Coolidge Fiduciary Advisors Llp sold 6,877 shares as Intuit (INTU)’s stock rose 4.61%. The Loring Wolcott & Coolidge Fiduciary Advisors Llp holds 1.20M shares with $170.84 million value, down from 1.21M last quarter. Intuit now has $44.00 billion valuation. The stock decreased 0.70% or $1.22 during the last trading session, reaching $172.1. About 2.07M shares traded or 53.28% up from the average. Intuit Inc. (NASDAQ:INTU) has risen 23.62% since February 23, 2017 and is uptrending. It has outperformed by 6.92% the S&P500.

Among 6 analysts covering BioLineRx (NASDAQ:BLRX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioLineRx had 23 analyst reports since July 27, 2015 according to SRatingsIntel. Roth Capital initiated BioLine Rx Ltd (NASDAQ:BLRX) on Thursday, August 3 with “Buy” rating. The rating was maintained by H.C. Wainwright on Tuesday, November 21 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $4.0 target in Tuesday, September 26 report. The stock of BioLine Rx Ltd (NASDAQ:BLRX) has “Buy” rating given on Tuesday, August 8 by Maxim Group. The firm has “Buy” rating given on Thursday, May 18 by Maxim Group. Maxim Group downgraded BioLine Rx Ltd (NASDAQ:BLRX) on Friday, August 12 to “Hold” rating. On Tuesday, September 26 the stock rating was maintained by Oppenheimer with “Buy”. The company was initiated on Thursday, December 21 by Oppenheimer. Maxim Group maintained the stock with “Buy” rating in Monday, July 10 report. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. See BioLine Rx Ltd (NASDAQ:BLRX) latest ratings:




17/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
21/12/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0 Initiate
21/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
04/12/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0 Maintain
04/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
21/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
18/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
26/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
26/09/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0 Maintain
12/09/2017 Broker: Oppenheimer Rating: Buy New Target: $3.0 Maintain

Since August 24, 2017, it had 0 insider purchases, and 11 selling transactions for $114.85 million activity. Shares for $1.13M were sold by Wernikoff Daniel A on Thursday, August 24. $750,338 worth of Intuit Inc. (NASDAQ:INTU) was sold by STANSBURY HENRY TAYLOE. COOK SCOTT D sold 183,333 shares worth $25.88M. Williams R Neil sold 184,585 shares worth $26.05M. 98,901 Intuit Inc. (NASDAQ:INTU) shares with value of $13.37M were sold by Goodarzi Sasan K. 1,868 Intuit Inc. (NASDAQ:INTU) shares with value of $265,839 were sold by FLOURNOY MARK J.

Investors sentiment decreased to 0.92 in Q3 2017. Its down 0.04, from 0.96 in 2017Q2. It fall, as 33 investors sold INTU shares while 249 reduced holdings. 66 funds opened positions while 193 raised stakes. 215.12 million shares or 0.10% less from 215.33 million shares in 2017Q2 were reported. Teacher Retirement Sys Of Texas, a Texas-based fund reported 33,717 shares. Howland Mngmt Lc owns 21,530 shares. Roundview Capital Llc holds 1,585 shares. Silvercrest Asset Mgmt Grp Incorporated Ltd reported 2,055 shares stake. Natl Mutual Insurance Federation Of Agricultural Cooperatives holds 0.05% or 18,000 shares. Lindsell Train Limited has 2.37 million shares. Lpl Fincl Limited Co holds 20,608 shares. Swiss Bank & Trust reported 897,373 shares stake. Buckingham Asset Management Lc reported 0.06% stake. The Ontario – Canada-based 1832 Asset Management LP has invested 0% in Intuit Inc. (NASDAQ:INTU). Huntington Bancorp holds 0.07% of its portfolio in Intuit Inc. (NASDAQ:INTU) for 27,878 shares. Denver Advisors Ltd Liability Com has 0.01% invested in Intuit Inc. (NASDAQ:INTU) for 2,150 shares. 14,218 are owned by Redmond Asset Management Lc. Regions reported 142,711 shares stake. Comgest Invsts Sas has 1.49% invested in Intuit Inc. (NASDAQ:INTU).

Loring Wolcott & Coolidge Fiduciary Advisors Llp increased Home Depot Inc (NYSE:HD) stake by 1,932 shares to 113,632 valued at $18.59M in 2017Q3. It also upped Microsoft Corp (NASDAQ:MSFT) stake by 5,295 shares and now owns 1.53M shares. Philip Morris International (NYSE:PM) was raised too.

Among 24 analysts covering Intuit (NASDAQ:INTU), 10 have Buy rating, 2 Sell and 12 Hold. Therefore 42% are positive. Intuit had 84 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Intuit Inc. (NASDAQ:INTU) earned “Equal-Weight” rating by Barclays Capital on Friday, July 15. The stock has “Buy” rating by UBS on Wednesday, September 9. The stock of Intuit Inc. (NASDAQ:INTU) earned “Buy” rating by Citigroup on Wednesday, August 24. Bank of America maintained it with “Buy” rating and $185 target in Wednesday, February 21 report. Barclays Capital upgraded the stock to “Overweight” rating in Thursday, September 10 report. Barclays Capital maintained Intuit Inc. (NASDAQ:INTU) rating on Tuesday, February 13. Barclays Capital has “Equal-Weight” rating and $168 target. On Wednesday, August 23 the stock rating was maintained by Credit Suisse with “Buy”. Deutsche Bank upgraded it to “Buy” rating and $120 target in Wednesday, August 19 report. The stock of Intuit Inc. (NASDAQ:INTU) has “Hold” rating given on Friday, July 21 by Stifel Nicolaus. As per Tuesday, September 13, the company rating was downgraded by Morgan Stanley.

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $109.32 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The companyÂ’s other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

The stock increased 1.00% or $0.01 during the last trading session, reaching $1.01. About 168,895 shares traded. BioLine Rx Ltd (NASDAQ:BLRX) has declined 6.10% since February 23, 2017 and is downtrending. It has underperformed by 22.80% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: